Early temporary reimbursement (ETR) schemes for new interventions targeting high unmet needs are increasingly applied in pharmaceutical policy. Crucial for these schemes is the assessment of unmet healthcare needs of patients and society. This study develops and tests a multi-criteria decision approach (MCDA) for assessing therapeutic and societal needs. The Belgian unmet needs commission, responsible for creating a list of unmet needs for the ETR programme, has tested this methodology to assess the needs in eight health conditions. For therapeutic need, three criteria were included (impact of the condition on quality of life and on life expectancy and inconvenience of current treatment); for societal need two criteria (condition-related he...
Background Multicriteria Decision Analysis (MCDA), a formal decision support framework, has been gro...
Objectives Resource allocation is a challenging issue faced by health policy decisionmakers requirin...
Background The diffusion of health technologies from translational research to reimbursement depe...
127 p.ill.,SCIENTIFIC REPORT 6 -- 1 INTRODUCTION 6 -- 1.1 COMPASSIONATE USE AND MEDICAL NEEDS PROGRA...
24 p.ill.,FOREWORD 1 -- SYNTHESIS 2 -- 1 BACKGROUND 3 -- 1.1 EARLY ACCESS TO PROMISING MEDICINES FOR...
The United Nations Sustainable Development Goals appoint that all Member States have agreed to try t...
Background Evaluation of integrated care programmes for individuals with multi-morbidity requires a ...
Patient access to orphan medicinal products (OMPs) is limited and varies between countries, reimburs...
Early access to medicines allows the prescription of a medicine before it is available in the public...
OBJECTIVES: When evaluating healthcare interventions, decision-makers are increasingly asked to cons...
Objectives: Multi-criteria decision analysis (MCDA) has been recommended to support policy making in...
Health care decisions are complex and involve confronting trade-offs between multiple, often conflic...
Background: Increasingly, multi-criteria decision analysis has gained importance as a method by whic...
none4siHealth technology assessment (HTA) is widely viewed as an essential component in good univers...
Background: Patient access to orphan medicinal products (OMPs) is limited and varies between countri...
Background Multicriteria Decision Analysis (MCDA), a formal decision support framework, has been gro...
Objectives Resource allocation is a challenging issue faced by health policy decisionmakers requirin...
Background The diffusion of health technologies from translational research to reimbursement depe...
127 p.ill.,SCIENTIFIC REPORT 6 -- 1 INTRODUCTION 6 -- 1.1 COMPASSIONATE USE AND MEDICAL NEEDS PROGRA...
24 p.ill.,FOREWORD 1 -- SYNTHESIS 2 -- 1 BACKGROUND 3 -- 1.1 EARLY ACCESS TO PROMISING MEDICINES FOR...
The United Nations Sustainable Development Goals appoint that all Member States have agreed to try t...
Background Evaluation of integrated care programmes for individuals with multi-morbidity requires a ...
Patient access to orphan medicinal products (OMPs) is limited and varies between countries, reimburs...
Early access to medicines allows the prescription of a medicine before it is available in the public...
OBJECTIVES: When evaluating healthcare interventions, decision-makers are increasingly asked to cons...
Objectives: Multi-criteria decision analysis (MCDA) has been recommended to support policy making in...
Health care decisions are complex and involve confronting trade-offs between multiple, often conflic...
Background: Increasingly, multi-criteria decision analysis has gained importance as a method by whic...
none4siHealth technology assessment (HTA) is widely viewed as an essential component in good univers...
Background: Patient access to orphan medicinal products (OMPs) is limited and varies between countri...
Background Multicriteria Decision Analysis (MCDA), a formal decision support framework, has been gro...
Objectives Resource allocation is a challenging issue faced by health policy decisionmakers requirin...
Background The diffusion of health technologies from translational research to reimbursement depe...